Research programme: neurological disorder therapeutics - AC Immune/ Essex Biotechnology

Drug Profile

Research programme: neurological disorder therapeutics - AC Immune/ Essex Biotechnology

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AC Immune; Essex Bio-Technology
  • Class Neuroprotectants; Proteins; Recombinant proteins
  • Mechanism of Action Neuropeptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Dementia

Most Recent Events

  • 22 May 2017 AC Immune and Essex Biotechnology agree to co-develop Neurological disorder therapeutics in Switzerland for Alzheimer's diease and Dementia
  • 22 May 2017 Early research in Alzheimer's disease in Switzerland (unspecified route)
  • 22 May 2017 Early research in Dementia in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top